These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 4795755)

  • 41. Effects of mifepristone on rabbit intraocular pressure in the presence and absence of dexamethasone.
    Green K; Cheeks L; Slagle T; Phillips CI
    Ophthalmic Res; 1990; 22(4):247-52. PubMed ID: 2089341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EFFECT OF CORTICOSTEROIDS ON INTRAOCULAR PRESSURE AND FLUID DYNAMICS. II. THE EFFECT OF DEXAMETHASONE IN THE GLAUCOMATOUS EYE.
    ARMALY MF
    Arch Ophthalmol; 1963 Oct; 70():492-9. PubMed ID: 14078871
    [No Abstract]   [Full Text] [Related]  

  • 43. Increased cellular sensitivity to glucocorticoids in primary open-angle glaucoma.
    Bigger JF; Palmberg PF; Becker B
    Invest Ophthalmol; 1972 Oct; 11(10):832-7. PubMed ID: 5071841
    [No Abstract]   [Full Text] [Related]  

  • 44. [Therapeutic experiences with Corti-Biciron ophthalmic ointment].
    Rüger K
    Dtsch Med J; 1970 Dec; 21(23):1462 passim. PubMed ID: 4321175
    [No Abstract]   [Full Text] [Related]  

  • 45. The glucose tolerance test and the response of intraocular pressure to topical corticosteroids.
    Becker B; LeBlanc RP
    Diabetes; 1970 Oct; 19(10):715-8. PubMed ID: 5474208
    [No Abstract]   [Full Text] [Related]  

  • 46. Steroid response in children.
    Brookes JL; Khaw PT
    Clin Exp Ophthalmol; 2005 Jun; 33(3):229-30. PubMed ID: 15932523
    [No Abstract]   [Full Text] [Related]  

  • 47. Aqueous humor alkalosis and marked reduction in ocular ascorbic acid content following long-term topical cortisone (9alpha-fluoro-16alpha-methylprednisolone).
    Virno M; Schirru A; Pecori-Giraldi J; Pellegrino N
    Ann Ophthalmol; 1974 Oct; 6(10):983-6, 989-92. PubMed ID: 4429318
    [No Abstract]   [Full Text] [Related]  

  • 48. Studies of the response to topical dexamethasone of glaucoma relatives.
    Paterson G
    Trans Ophthalmol Soc U K (1962); 1965; 85():295-305. PubMed ID: 5227191
    [No Abstract]   [Full Text] [Related]  

  • 49. EFFECT OF CORTICOSTEROIDS ON INTRAOCULAR PRESSURE AND FLUID DYNAMICS. I. THE EFFECT OF DEXAMETHASONE IN THE NORMAL EYE.
    ARMALY MF
    Arch Ophthalmol; 1963 Oct; 70():482-91. PubMed ID: 14078870
    [No Abstract]   [Full Text] [Related]  

  • 50. Enhanced ocular hypotensive response to timolol in rabbits with prior dexamethasone treatment.
    Schwartz B; Rom ME
    J Ocul Pharmacol Ther; 2001 Feb; 17(1):27-33. PubMed ID: 11322635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of adenosine receptors in resveratrol-induced intraocular pressure lowering in rats with steroid-induced ocular hypertension.
    Razali N; Agarwal R; Agarwal P; Kumar S; Tripathy M; Vasudevan S; Crowston JG; Ismail NM
    Clin Exp Ophthalmol; 2015; 43(1):54-66. PubMed ID: 24995479
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effect of instillations of 0.25% rausedyl on ocular accommodation and hemo- and hydrodynamics of the eye].
    Levchenko OG; Zakhidov BA; Shirin VV
    Oftalmol Zh; 1981; 36(4):224-8. PubMed ID: 7301254
    [No Abstract]   [Full Text] [Related]  

  • 53. Reduction of intraocular pressure with dexamethasone.
    Jackson H
    Lancet; 1971 Aug; 2(7720):375. PubMed ID: 4105071
    [No Abstract]   [Full Text] [Related]  

  • 54. L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals.
    Sugrue MF; Gautheron P; Mallorga P; Nolan TE; Graham SL; Schwam H; Shepard KL; Smith RL
    Br J Pharmacol; 1990 Jan; 99(1):59-64. PubMed ID: 2110013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of ocular and general safety following repeated dosing of dexamethasone phosphate delivered by transscleral iontophoresis in rabbits.
    Patane MA; Schubert W; Sanford T; Gee R; Burgos M; Isom WP; Ruiz-Perez B
    J Ocul Pharmacol Ther; 2013 Oct; 29(8):760-9. PubMed ID: 23844757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DEX implant intravitreal injection, sustained intraocular hypertension, and steroid-induced glaucoma in patients with no risk factors.
    Rezkallah A; Kodjikian L; Malclès A; Dot C
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):219-220. PubMed ID: 28801709
    [No Abstract]   [Full Text] [Related]  

  • 57. The heritable nature of dexamethasone-induced ocular hypertension.
    Armaly MF
    Arch Ophthalmol; 1966 Jan; 75(1):32-5. PubMed ID: 5900502
    [No Abstract]   [Full Text] [Related]  

  • 58. Intraocular pressure response to topical dexamethasone as a predictor for the development of primary open-angle glaucoma.
    Lewis JM; Priddy T; Judd J; Gordon MO; Kass MA; Kolker AE; Becker B
    Am J Ophthalmol; 1988 Nov; 106(5):607-12. PubMed ID: 3189477
    [TBL] [Abstract][Full Text] [Related]  

  • 59. OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.
    Chin EK; Almeida DRP; Velez G; Xu K; Peraire M; Corbella M; Elshatory YM; Kwon YH; Gehrs KM; Boldt HC; Sohn EH; Russell SR; Folk JC; Mahajan VB
    Retina; 2017 Jul; 37(7):1345-1351. PubMed ID: 27806001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response #1 to Immediate Intraocular Pressure Tendency Following Intravitreal Delivery of Dexamethasone Implant; Alagöz et al. J. Ocul. Pharmacol. Ther. 32:44-49, 2016.
    Çekiç O; Turhan SA
    J Ocul Pharmacol Ther; 2016; 32(6):343. PubMed ID: 27058573
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.